TY  - CONF
AU  - Masnikosa, Romana
AU  - Pirić, David
AU  - Cvetković, Zorica
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12413
AB  - Both cancer and inflammation are almost invariably accompanied by lipidome dysregulation. Hence, various lipid species have been reported as candidate markers for many solid tumours1-3. However, neither the global lipidome nor sub-lipidome of inflammatory pathways in Non-Hodgkin lymphoma (NHL) has been studied. In order to fill this gap and shed light on the inflammatory pathways accompanying NHL, we designed a targeted liquid chromatography – Multiple Reaction Monitoring of bioactive lipids/lipid mediators in plasma of female patients with Diffuse Large B-cell Lymphoma (DLBCL), the most often type of NHL. We chose to quantify lipids known or hypothesized to be involved in inflammation and cancer progression along with their membrane precursors. In a pilot study encompassing plasma samples from 17 DLBCL patients and 21 BMI-matched controls, we analysed levels of pro-inlammatory arachidonic acid (AA)-derived oxylipins, focusing on lipoxygenase (LOX) and cytochrome P450 monooxygenase products: hydroxyeicosatetraenoic acids (HETEs) and dihydroxyeicosatrienoic acids; several AA-containing phospholipids (PLs); specificlysophospholipid subclasses; sphingomyelins (SMs), sphingosine 1-phosphate (S1P) and polyunsaturated fatty acids. Data were subjected to classical statistics and multivariate unsupervised and supervised machine learning (ML) algorithms. The DLBCL status was profoundly associated with altered S1P, SM 34:1, SM 36:1 and phosphatidylinositol PI 34:1 abundance. On the other hand, eicosanoids 12(S)-HETE, 15(S)-HETE and thromboxane B2 were major lipid species dis criminating between DLBCL and healthy status, as well as lysophosphatidylinositol LPI 20:4. The correlations between lipid species varied considerably between the cancer and controls, reflecting significant changes in lipid metabolic and/or signalling pathways, particularly those within LOX pathway and cell membrane PL remodelling. We suggest S1P, SM 36:1, SM 34:1 and PI 34:1 may beviewed as lipid signatures of DLBCL. Furthermore, these four lipid species could serve as a basis for the prospective validation in larger DLBCL/NHL clinical studies. As far as we know, this is the first plasma lipid profiling in DLBCL/NHL and, as such, brings new knowledge on the metabolic basis of inflammation in this cancer. The added value of our plasma lipid profiling in DLBCL is a deeper understanding of particulate lipid dysregulations in this tumour.
PB  - Kragujevac : Faculty of Science, University of Kragujevac
C3  - SePA : VI Symposium of a Serbian proteomic society: „Discussion and Application of New Methods of Proteomics“ : Book of abstracts
T1  - Plasma Profile of Inflamatory Mediators in NHL Patients
SP  - OP5
EP  - OP5
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12413
ER  - 

@conference{
author = "Masnikosa, Romana and Pirić, David and Cvetković, Zorica",
year = "2023",
abstract = "Both cancer and inflammation are almost invariably accompanied by lipidome dysregulation. Hence, various lipid species have been reported as candidate markers for many solid tumours1-3. However, neither the global lipidome nor sub-lipidome of inflammatory pathways in Non-Hodgkin lymphoma (NHL) has been studied. In order to fill this gap and shed light on the inflammatory pathways accompanying NHL, we designed a targeted liquid chromatography – Multiple Reaction Monitoring of bioactive lipids/lipid mediators in plasma of female patients with Diffuse Large B-cell Lymphoma (DLBCL), the most often type of NHL. We chose to quantify lipids known or hypothesized to be involved in inflammation and cancer progression along with their membrane precursors. In a pilot study encompassing plasma samples from 17 DLBCL patients and 21 BMI-matched controls, we analysed levels of pro-inlammatory arachidonic acid (AA)-derived oxylipins, focusing on lipoxygenase (LOX) and cytochrome P450 monooxygenase products: hydroxyeicosatetraenoic acids (HETEs) and dihydroxyeicosatrienoic acids; several AA-containing phospholipids (PLs); specificlysophospholipid subclasses; sphingomyelins (SMs), sphingosine 1-phosphate (S1P) and polyunsaturated fatty acids. Data were subjected to classical statistics and multivariate unsupervised and supervised machine learning (ML) algorithms. The DLBCL status was profoundly associated with altered S1P, SM 34:1, SM 36:1 and phosphatidylinositol PI 34:1 abundance. On the other hand, eicosanoids 12(S)-HETE, 15(S)-HETE and thromboxane B2 were major lipid species dis criminating between DLBCL and healthy status, as well as lysophosphatidylinositol LPI 20:4. The correlations between lipid species varied considerably between the cancer and controls, reflecting significant changes in lipid metabolic and/or signalling pathways, particularly those within LOX pathway and cell membrane PL remodelling. We suggest S1P, SM 36:1, SM 34:1 and PI 34:1 may beviewed as lipid signatures of DLBCL. Furthermore, these four lipid species could serve as a basis for the prospective validation in larger DLBCL/NHL clinical studies. As far as we know, this is the first plasma lipid profiling in DLBCL/NHL and, as such, brings new knowledge on the metabolic basis of inflammation in this cancer. The added value of our plasma lipid profiling in DLBCL is a deeper understanding of particulate lipid dysregulations in this tumour.",
publisher = "Kragujevac : Faculty of Science, University of Kragujevac",
journal = "SePA : VI Symposium of a Serbian proteomic society: „Discussion and Application of New Methods of Proteomics“ : Book of abstracts",
title = "Plasma Profile of Inflamatory Mediators in NHL Patients",
pages = "OP5-OP5",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12413"
}

Masnikosa, R., Pirić, D.,& Cvetković, Z.. (2023). Plasma Profile of Inflamatory Mediators in NHL Patients. in SePA : VI Symposium of a Serbian proteomic society: „Discussion and Application of New Methods of Proteomics“ : Book of abstracts
Kragujevac : Faculty of Science, University of Kragujevac., OP5-OP5.
https://hdl.handle.net/21.15107/rcub_vinar_12413

Masnikosa R, Pirić D, Cvetković Z. Plasma Profile of Inflamatory Mediators in NHL Patients. in SePA : VI Symposium of a Serbian proteomic society: „Discussion and Application of New Methods of Proteomics“ : Book of abstracts. 2023;:OP5-OP5.
https://hdl.handle.net/21.15107/rcub_vinar_12413 .

Masnikosa, Romana, Pirić, David, Cvetković, Zorica, "Plasma Profile of Inflamatory Mediators in NHL Patients" in SePA : VI Symposium of a Serbian proteomic society: „Discussion and Application of New Methods of Proteomics“ : Book of abstracts (2023):OP5-OP5,
https://hdl.handle.net/21.15107/rcub_vinar_12413 .

TY  - CONF
AU  - Masnikosa, Romana
AU  - Pirić, David
AU  - Cvetković, Zorica
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12257
AB  - Both cancer and inflammation are almost invariably accompanied by lipidome dysregulation. Hence, various lipid species have been reported as candidate markers for many solid tumours 1-3 .However, neitherthe globallipidome norsub-lipidome ofinflammatory pathways in Non-Hodgkin lymphoma (NHL) has been studied. In order to fill this gap and shed light on the inflammatory pathways accompanying NHL, we designed a targeted liquid chromatography – Multiple Reaction Monitoring of bioactive lipids/lipid mediators in plasma of female patients with Diffuse Large B-cell Lymphoma (DLBCL), the most often type of NHL. We chose to quantify lipids known or hypothesized to be involved in inflammation and cancer progression along with theirmembrane precursors. In a pilot study encompassing plasma samples from 17 DLBCL patients and 21 BMI-matched controls, we analysed levels of pro-inlammatory arachidonic acid (AA)-derived oxylipins, focusing on lipoxygenase (LOX) and cytochrome P450 monooxygenase products: hydroxyeicosatetraenoic acids (HETEs) and dihydroxyeicosatrienoic acids; several AA-containing phospholipids (PLs); specificlysophospholipid subclasses; sphingomyelins (SMs), sphingosine 1-phosphate (S1P) and polyunsaturated fatty acids. Data were subjected to classical statistics and multivariate unsupervised and supervised machine learning (ML) algorithms. The DLBCL status was profoundly associated with altered S1P, SM 34:1, SM 36:1 and phosphatidylinositol PI 34:1 abundance. On the other hand, eicosanoids 12(S)-HETE, 15(S)-HETE and thromboxane B2 were major lipid species discriminating between DLBCL and healthy status, as well as lysophosphatidylinositol LPI 20:4. The correlations between lipid species varied considerably between the cancer and controls, reflecting significant changes in lipid metabolic and/or signalling pathways, particularly those within LOX pathway and cell membrane PL remodelling. We suggest S1P, SM 36:1, SM 34:1 and PI 34:1 may beviewed as lipid signatures of DLBCL. Furthermore, these four lipid species could serve asa basis for the prospective validation in larger DLBCL/NHL clinical studies. As far as we know, this is the first plasma lipid profiling in DLBCL/NHL and, as such, brings new knowledge on the metabolic basis of inflammation in this cancer. The added value of our plasma lipid profiling in DLBCL is a deeper understanding of particulate lipid dysregulations in this tumour
PB  - Belgrade : Faculty of Science, University of Kragujevac
C3  - SePA : VI Symposium of a Serbian proteomic society: „Discussion and Application of New Methods of Proteomics“ : Book of abstracts
T1  - Plasma Profile of Inflamatory Mediators in NHL Patients
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12257
ER  - 

@conference{
author = "Masnikosa, Romana and Pirić, David and Cvetković, Zorica",
year = "2023",
abstract = "Both cancer and inflammation are almost invariably accompanied by lipidome dysregulation. Hence, various lipid species have been reported as candidate markers for many solid tumours 1-3 .However, neitherthe globallipidome norsub-lipidome ofinflammatory pathways in Non-Hodgkin lymphoma (NHL) has been studied. In order to fill this gap and shed light on the inflammatory pathways accompanying NHL, we designed a targeted liquid chromatography – Multiple Reaction Monitoring of bioactive lipids/lipid mediators in plasma of female patients with Diffuse Large B-cell Lymphoma (DLBCL), the most often type of NHL. We chose to quantify lipids known or hypothesized to be involved in inflammation and cancer progression along with theirmembrane precursors. In a pilot study encompassing plasma samples from 17 DLBCL patients and 21 BMI-matched controls, we analysed levels of pro-inlammatory arachidonic acid (AA)-derived oxylipins, focusing on lipoxygenase (LOX) and cytochrome P450 monooxygenase products: hydroxyeicosatetraenoic acids (HETEs) and dihydroxyeicosatrienoic acids; several AA-containing phospholipids (PLs); specificlysophospholipid subclasses; sphingomyelins (SMs), sphingosine 1-phosphate (S1P) and polyunsaturated fatty acids. Data were subjected to classical statistics and multivariate unsupervised and supervised machine learning (ML) algorithms. The DLBCL status was profoundly associated with altered S1P, SM 34:1, SM 36:1 and phosphatidylinositol PI 34:1 abundance. On the other hand, eicosanoids 12(S)-HETE, 15(S)-HETE and thromboxane B2 were major lipid species discriminating between DLBCL and healthy status, as well as lysophosphatidylinositol LPI 20:4. The correlations between lipid species varied considerably between the cancer and controls, reflecting significant changes in lipid metabolic and/or signalling pathways, particularly those within LOX pathway and cell membrane PL remodelling. We suggest S1P, SM 36:1, SM 34:1 and PI 34:1 may beviewed as lipid signatures of DLBCL. Furthermore, these four lipid species could serve asa basis for the prospective validation in larger DLBCL/NHL clinical studies. As far as we know, this is the first plasma lipid profiling in DLBCL/NHL and, as such, brings new knowledge on the metabolic basis of inflammation in this cancer. The added value of our plasma lipid profiling in DLBCL is a deeper understanding of particulate lipid dysregulations in this tumour",
publisher = "Belgrade : Faculty of Science, University of Kragujevac",
journal = "SePA : VI Symposium of a Serbian proteomic society: „Discussion and Application of New Methods of Proteomics“ : Book of abstracts",
title = "Plasma Profile of Inflamatory Mediators in NHL Patients",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12257"
}

Masnikosa, R., Pirić, D.,& Cvetković, Z.. (2023). Plasma Profile of Inflamatory Mediators in NHL Patients. in SePA : VI Symposium of a Serbian proteomic society: „Discussion and Application of New Methods of Proteomics“ : Book of abstracts
Belgrade : Faculty of Science, University of Kragujevac..
https://hdl.handle.net/21.15107/rcub_vinar_12257

Masnikosa R, Pirić D, Cvetković Z. Plasma Profile of Inflamatory Mediators in NHL Patients. in SePA : VI Symposium of a Serbian proteomic society: „Discussion and Application of New Methods of Proteomics“ : Book of abstracts. 2023;.
https://hdl.handle.net/21.15107/rcub_vinar_12257 .

Masnikosa, Romana, Pirić, David, Cvetković, Zorica, "Plasma Profile of Inflamatory Mediators in NHL Patients" in SePA : VI Symposium of a Serbian proteomic society: „Discussion and Application of New Methods of Proteomics“ : Book of abstracts (2023),
https://hdl.handle.net/21.15107/rcub_vinar_12257 .

TY  - JOUR
AU  - Masnikosa, Romana
AU  - Pirić, David
AU  - Post, Julia Maria
AU  - Cvetković, Zorica
AU  - Petrović, Snježana
AU  - Paunović, Marija
AU  - Vučić, Vesna
AU  - Bindila, Laura
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/11437
AB  - Lipidome dysregulation is a hallmark of cancer and inflammation. The global plasma lipidome and sub-lipidome of inflammatory pathways have not been reported in diffuse large B-cell lymphoma (DLBCL). In a pilot study of plasma lipid variation in female DLBCL patients and BMI-matched disease-free controls, we performed targeted lipidomics using LC-MRM to quantify lipid mediators of inflammation and immunity, and those known or hypothesised to be involved in cancer progression: sphingolipids, resolvin D1, arachidonic acid (AA)-derived oxylipins, such as hydroxyeicosatetraenoic acids (HETEs) and dihydroxyeicosatrienoic acids, along with their membrane structural precursors. We report on the role of the eicosanoids in the separation of DLBCL from controls, along with lysophosphatidylinositol LPI 20:4, implying notable changes in lipid metabolic and/or signalling pathways, particularly pertaining to AA lipoxygenase pathway and glycerophospholipid remodelling in the cell membrane. We suggest here the set of S1P, SM 36:1, SM 34:1 and PI 34:1 as DLBCL lipid signatures which could serve as a basis for the prospective validation in larger DLBCL cohorts. Additionally, untargeted lipidomics indicates a substantial change in the overall lipid metabolism in DLBCL. The plasma lipid profiling of DLBCL patients helps to better understand the specific lipid dysregulations and pathways in this cancer.
T2  - Cancers
T1  - Disturbed Plasma Lipidomic Profiles in Females with Diffuse Large B-Cell Lymphoma: A Pilot Study
VL  - 15
IS  - 14
SP  - 3653
DO  - 10.3390/cancers15143653
ER  - 

@article{
author = "Masnikosa, Romana and Pirić, David and Post, Julia Maria and Cvetković, Zorica and Petrović, Snježana and Paunović, Marija and Vučić, Vesna and Bindila, Laura",
year = "2023",
abstract = "Lipidome dysregulation is a hallmark of cancer and inflammation. The global plasma lipidome and sub-lipidome of inflammatory pathways have not been reported in diffuse large B-cell lymphoma (DLBCL). In a pilot study of plasma lipid variation in female DLBCL patients and BMI-matched disease-free controls, we performed targeted lipidomics using LC-MRM to quantify lipid mediators of inflammation and immunity, and those known or hypothesised to be involved in cancer progression: sphingolipids, resolvin D1, arachidonic acid (AA)-derived oxylipins, such as hydroxyeicosatetraenoic acids (HETEs) and dihydroxyeicosatrienoic acids, along with their membrane structural precursors. We report on the role of the eicosanoids in the separation of DLBCL from controls, along with lysophosphatidylinositol LPI 20:4, implying notable changes in lipid metabolic and/or signalling pathways, particularly pertaining to AA lipoxygenase pathway and glycerophospholipid remodelling in the cell membrane. We suggest here the set of S1P, SM 36:1, SM 34:1 and PI 34:1 as DLBCL lipid signatures which could serve as a basis for the prospective validation in larger DLBCL cohorts. Additionally, untargeted lipidomics indicates a substantial change in the overall lipid metabolism in DLBCL. The plasma lipid profiling of DLBCL patients helps to better understand the specific lipid dysregulations and pathways in this cancer.",
journal = "Cancers",
title = "Disturbed Plasma Lipidomic Profiles in Females with Diffuse Large B-Cell Lymphoma: A Pilot Study",
volume = "15",
number = "14",
pages = "3653",
doi = "10.3390/cancers15143653"
}

Masnikosa, R., Pirić, D., Post, J. M., Cvetković, Z., Petrović, S., Paunović, M., Vučić, V.,& Bindila, L.. (2023). Disturbed Plasma Lipidomic Profiles in Females with Diffuse Large B-Cell Lymphoma: A Pilot Study. in Cancers, 15(14), 3653.
https://doi.org/10.3390/cancers15143653

Masnikosa R, Pirić D, Post JM, Cvetković Z, Petrović S, Paunović M, Vučić V, Bindila L. Disturbed Plasma Lipidomic Profiles in Females with Diffuse Large B-Cell Lymphoma: A Pilot Study. in Cancers. 2023;15(14):3653.
doi:10.3390/cancers15143653 .

Masnikosa, Romana, Pirić, David, Post, Julia Maria, Cvetković, Zorica, Petrović, Snježana, Paunović, Marija, Vučić, Vesna, Bindila, Laura, "Disturbed Plasma Lipidomic Profiles in Females with Diffuse Large B-Cell Lymphoma: A Pilot Study" in Cancers, 15, no. 14 (2023):3653,
https://doi.org/10.3390/cancers15143653 . .

TY  - CONF
AU  - Cvetković, Stefana
AU  - Đukanović, S.
AU  - Mitić-Ćulafić, Dragana
AU  - Nastasijević, Branislav J.
AU  - Knežević-Vukčević, Jelena
AU  - Nikolić, Biljana
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8627
AB  - During high-temperature cooking of protein rich foods, especially meat and fish, heterocyclic aromatic amines can be formed. These amines are a class of potent mutagens that can cause alterations in the structure of DNA and chromosomes. In recent decades, research has been focused on investigating plants and their phytochemicals as potential antimutagens. The aim of this study was to examine the anti-genotoxic effect of methanolic root and leaf extracts of Gentiana lutea against the food mutagens 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) produced in thermally processed meat. To determine the protective potential of extracts, the alkaline comet assay was applied. The results obtained indicated strong anti-genotoxic effect of both extracts against the tested mutagens. The highest inhibition of IQ-induced genotoxicity was recorded for leaf extract (72%). Regarding PhiP, root extract achieved inhibition of 80% of DNA damage, so was more successful than leaf extract. The data obtained in this study stimulates further research of G. lutea extracts and its constituents as potential dietary supplements in improving human health. © Published under licence by IOP Publishing Ltd.
C3  - IOP Conference Series: Earth and Environmental Science
T1  - Protective effect of Gentiana lutea root and leaf extracts against heterocyclic aromatic amines IQ and PhIP produced in thermally processed meat
VL  - 333
IS  - 1
SP  - UNSP 012052
DO  - 10.1088/1755-1315/333/1/012052
ER  - 

@conference{
author = "Cvetković, Stefana and Đukanović, S. and Mitić-Ćulafić, Dragana and Nastasijević, Branislav J. and Knežević-Vukčević, Jelena and Nikolić, Biljana",
year = "2019",
abstract = "During high-temperature cooking of protein rich foods, especially meat and fish, heterocyclic aromatic amines can be formed. These amines are a class of potent mutagens that can cause alterations in the structure of DNA and chromosomes. In recent decades, research has been focused on investigating plants and their phytochemicals as potential antimutagens. The aim of this study was to examine the anti-genotoxic effect of methanolic root and leaf extracts of Gentiana lutea against the food mutagens 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) produced in thermally processed meat. To determine the protective potential of extracts, the alkaline comet assay was applied. The results obtained indicated strong anti-genotoxic effect of both extracts against the tested mutagens. The highest inhibition of IQ-induced genotoxicity was recorded for leaf extract (72%). Regarding PhiP, root extract achieved inhibition of 80% of DNA damage, so was more successful than leaf extract. The data obtained in this study stimulates further research of G. lutea extracts and its constituents as potential dietary supplements in improving human health. © Published under licence by IOP Publishing Ltd.",
journal = "IOP Conference Series: Earth and Environmental Science",
title = "Protective effect of Gentiana lutea root and leaf extracts against heterocyclic aromatic amines IQ and PhIP produced in thermally processed meat",
volume = "333",
number = "1",
pages = "UNSP 012052",
doi = "10.1088/1755-1315/333/1/012052"
}

Cvetković, S., Đukanović, S., Mitić-Ćulafić, D., Nastasijević, B. J., Knežević-Vukčević, J.,& Nikolić, B.. (2019). Protective effect of Gentiana lutea root and leaf extracts against heterocyclic aromatic amines IQ and PhIP produced in thermally processed meat. in IOP Conference Series: Earth and Environmental Science, 333(1), UNSP 012052.
https://doi.org/10.1088/1755-1315/333/1/012052

Cvetković S, Đukanović S, Mitić-Ćulafić D, Nastasijević BJ, Knežević-Vukčević J, Nikolić B. Protective effect of Gentiana lutea root and leaf extracts against heterocyclic aromatic amines IQ and PhIP produced in thermally processed meat. in IOP Conference Series: Earth and Environmental Science. 2019;333(1):UNSP 012052.
doi:10.1088/1755-1315/333/1/012052 .

Cvetković, Stefana, Đukanović, S., Mitić-Ćulafić, Dragana, Nastasijević, Branislav J., Knežević-Vukčević, Jelena, Nikolić, Biljana, "Protective effect of Gentiana lutea root and leaf extracts against heterocyclic aromatic amines IQ and PhIP produced in thermally processed meat" in IOP Conference Series: Earth and Environmental Science, 333, no. 1 (2019):UNSP 012052,
https://doi.org/10.1088/1755-1315/333/1/012052 . .

TY  - JOUR
AU  - Cvetković, Zorica
AU  - Milošević, Maja
AU  - Cvetković, Bora
AU  - Masnikosa, Romana
AU  - Arsić, Aleksandra
AU  - Petrović, Snježana
AU  - Vučić, Vesna
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1489
AB  - Limited studies have been performed to associate abnormal phospholipid (PL) profile and disease activity in hematological malignancies, including non-Hodgkin lymphoma (NHL). The aim of his study was to evaluate the levels of plasma PL fractions in NHL patients, in response to chemotherapy. Forty non-treated patients with NHL and 25 healthy individuals were recruited. Blood samples from patients were taken before chemotherapy, after 3 cycles and after the end of the treatment, and PL fractions were resolved by one-dimensional thin-layer chromatography. To assess potential relationship between plasma PL profile and response to therapy, patients were divided according to clinical outcome in 3 groups: complete remission (CR), stable disease (SD) and progression (PG). Despite significant differences between NHL patients and healthy controls, no differences were found at baseline among patients divided according to clinical outcome. During and after chemotherapy important alterations in PL profile were observed. Levels of total PLs and all PL fractions decreased in patients with PG while in patients who responded to therapy (CR, SD) PLs significantly increased. Results of our study suggest that changes of total PLs and PL fractions during the therapy are associated with the effects of therapy and clinical outcome in patients with NHL. (C) 2017 Elsevier Ltd. All rights reserved.
T2  - Leukemia Research
T1  - Plasma phospholipid changes are associated with response to chemotherapy in non-Hodgkin lymphoma patients
VL  - 54
SP  - 39
EP  - 46
DO  - 10.1016/j.leukres.2017.01.004
ER  - 

@article{
author = "Cvetković, Zorica and Milošević, Maja and Cvetković, Bora and Masnikosa, Romana and Arsić, Aleksandra and Petrović, Snježana and Vučić, Vesna",
year = "2017",
abstract = "Limited studies have been performed to associate abnormal phospholipid (PL) profile and disease activity in hematological malignancies, including non-Hodgkin lymphoma (NHL). The aim of his study was to evaluate the levels of plasma PL fractions in NHL patients, in response to chemotherapy. Forty non-treated patients with NHL and 25 healthy individuals were recruited. Blood samples from patients were taken before chemotherapy, after 3 cycles and after the end of the treatment, and PL fractions were resolved by one-dimensional thin-layer chromatography. To assess potential relationship between plasma PL profile and response to therapy, patients were divided according to clinical outcome in 3 groups: complete remission (CR), stable disease (SD) and progression (PG). Despite significant differences between NHL patients and healthy controls, no differences were found at baseline among patients divided according to clinical outcome. During and after chemotherapy important alterations in PL profile were observed. Levels of total PLs and all PL fractions decreased in patients with PG while in patients who responded to therapy (CR, SD) PLs significantly increased. Results of our study suggest that changes of total PLs and PL fractions during the therapy are associated with the effects of therapy and clinical outcome in patients with NHL. (C) 2017 Elsevier Ltd. All rights reserved.",
journal = "Leukemia Research",
title = "Plasma phospholipid changes are associated with response to chemotherapy in non-Hodgkin lymphoma patients",
volume = "54",
pages = "39-46",
doi = "10.1016/j.leukres.2017.01.004"
}

Cvetković, Z., Milošević, M., Cvetković, B., Masnikosa, R., Arsić, A., Petrović, S.,& Vučić, V.. (2017). Plasma phospholipid changes are associated with response to chemotherapy in non-Hodgkin lymphoma patients. in Leukemia Research, 54, 39-46.
https://doi.org/10.1016/j.leukres.2017.01.004

Cvetković Z, Milošević M, Cvetković B, Masnikosa R, Arsić A, Petrović S, Vučić V. Plasma phospholipid changes are associated with response to chemotherapy in non-Hodgkin lymphoma patients. in Leukemia Research. 2017;54:39-46.
doi:10.1016/j.leukres.2017.01.004 .

Cvetković, Zorica, Milošević, Maja, Cvetković, Bora, Masnikosa, Romana, Arsić, Aleksandra, Petrović, Snježana, Vučić, Vesna, "Plasma phospholipid changes are associated with response to chemotherapy in non-Hodgkin lymphoma patients" in Leukemia Research, 54 (2017):39-46,
https://doi.org/10.1016/j.leukres.2017.01.004 . .

TY  - JOUR
AU  - Mitrović, Bojan
AU  - Gluvić, Zoran
AU  - Samardžić, Vladimir
AU  - Obradović, Milan M.
AU  - Lačković, Milena
AU  - Cvetković, Zorica
AU  - Pavlović, Aleksandar
AU  - Isenović, Esma R.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10310
AB  - Tromboza portne vene (TPV) je retko oboljenje splanhničke cirkulacije, koje najčešće nastaje sadejstvom više lokalnih i/ili sistemskih faktora. Ukoliko TPV komplikuje osnovnu bolest, ona pogoršava njenu prognozu, a konkomitantno se leče obe. Iako se najčešće javlja u sklopu ciroze jetre, malignih bolesti abdominalnih organa i nekih hemopatija, postoji i idiopatska TPV, koja se definiše ekskluzijom svih poznatih uzroka TPV. U ovom radu je prikazan slučaj hronične idioptaske TPV.
AB  - Portal vein thrombosis (PVT) is a rare disorder of splanchnic circulation, frequently caused by concomitant presence of local and/or systemic factors. When portal vein thrombosis complicates causative diseases, it will worsen their prognosis, and in such a case, the causative disease and PVT are treated concomitantly. Despite the fact that PVT frequently complicates liver cirrhosis, intraabdominal malignancies, and some hematological diseases, after all causes are excluded, one can define idiopathic portal vein thrombosis. In this study we have described the case of idiopathic chronical portal vein thrombosis.
T2  - Medicinska istraživanja
T1  - Hronična idiopatska Tromboza portne vene - prikaz slučaja
T1  - Chronic idiopathic portal vein thrombosis: A case study
VL  - 50
IS  - 2
SP  - 13
EP  - 17
DO  - 10.5937/MedIst1602013M
ER  - 

@article{
author = "Mitrović, Bojan and Gluvić, Zoran and Samardžić, Vladimir and Obradović, Milan M. and Lačković, Milena and Cvetković, Zorica and Pavlović, Aleksandar and Isenović, Esma R.",
year = "2016",
abstract = "Tromboza portne vene (TPV) je retko oboljenje splanhničke cirkulacije, koje najčešće nastaje sadejstvom više lokalnih i/ili sistemskih faktora. Ukoliko TPV komplikuje osnovnu bolest, ona pogoršava njenu prognozu, a konkomitantno se leče obe. Iako se najčešće javlja u sklopu ciroze jetre, malignih bolesti abdominalnih organa i nekih hemopatija, postoji i idiopatska TPV, koja se definiše ekskluzijom svih poznatih uzroka TPV. U ovom radu je prikazan slučaj hronične idioptaske TPV., Portal vein thrombosis (PVT) is a rare disorder of splanchnic circulation, frequently caused by concomitant presence of local and/or systemic factors. When portal vein thrombosis complicates causative diseases, it will worsen their prognosis, and in such a case, the causative disease and PVT are treated concomitantly. Despite the fact that PVT frequently complicates liver cirrhosis, intraabdominal malignancies, and some hematological diseases, after all causes are excluded, one can define idiopathic portal vein thrombosis. In this study we have described the case of idiopathic chronical portal vein thrombosis.",
journal = "Medicinska istraživanja",
title = "Hronična idiopatska Tromboza portne vene - prikaz slučaja, Chronic idiopathic portal vein thrombosis: A case study",
volume = "50",
number = "2",
pages = "13-17",
doi = "10.5937/MedIst1602013M"
}

Mitrović, B., Gluvić, Z., Samardžić, V., Obradović, M. M., Lačković, M., Cvetković, Z., Pavlović, A.,& Isenović, E. R.. (2016). Hronična idiopatska Tromboza portne vene - prikaz slučaja. in Medicinska istraživanja, 50(2), 13-17.
https://doi.org/10.5937/MedIst1602013M

Mitrović B, Gluvić Z, Samardžić V, Obradović MM, Lačković M, Cvetković Z, Pavlović A, Isenović ER. Hronična idiopatska Tromboza portne vene - prikaz slučaja. in Medicinska istraživanja. 2016;50(2):13-17.
doi:10.5937/MedIst1602013M .

Mitrović, Bojan, Gluvić, Zoran, Samardžić, Vladimir, Obradović, Milan M., Lačković, Milena, Cvetković, Zorica, Pavlović, Aleksandar, Isenović, Esma R., "Hronična idiopatska Tromboza portne vene - prikaz slučaja" in Medicinska istraživanja, 50, no. 2 (2016):13-17,
https://doi.org/10.5937/MedIst1602013M . .